ACE2-Fc-anti-IL-6R scfv fusion protein (Shanghai Keqi Pharmaceutical Technology)

N/A

Report date: 2025/01/26 18:30:29

Base Information

Drug NameACE2-Fc-anti-IL-6R scfv fusion protein (Shanghai Keqi Pharmaceutical Technology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsIL-6 receptor antagonists
TargetsIL-6 receptorCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A